The present application describes heterocyclic GLP-1 agonists, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating GLP-1-associated diseases, disorders, and conditions.
Generic options for GLP-1 Receptor Agonist pharmaceutical drugs, including patent status, patent expiration dates, and more.
Researchers are exploring GLP-1 R-based multi-agonists and combination therapies to bridge this divide. This article reviews patents related to these strategies as well as traditional approaches in the development of GLP-1RAs.
The GLP-1 patent landscape highlights several strategic realities for pharmaceutical companies and generic manufacturers. GLP-1 patent activity continues to accelerate, reflecting sustained investment as the market expands beyond diabetes into obesity and cardiovascular therapies.
This Special Communication used data from the US Food and Drug Administration to analyze how manufacturers of brand-name glucagon-like peptide 1 (GLP-1) receptor agonists have used patent and regulatory systems to extend periods of market exclusivity.
Furthermore, visual representations like the one above help us fully grasp the concept of Glp-1 Agonist International Patents.
Download Citation | An updated patent review of GLP-1 receptor agonists (2020-present) | Introduction: Type 2 diabetes (T2DM) and obesity present significant global health issues, requiring the ...
